Men with BRCA1 and BRCA2 gene mutations should get annual prostate cancer screening

Testing for the prostate-specific antigen (PSA) in the general population is not advised because of the risk that elevated levels can pick out men with clinically insignificant prostate cancers – meaning that men may undergo unnecessary MRI scans, invasive biopsies, and treatments.ICR scientists have been working to understand who is at the highest risk of the disease, and who could therefore benefit from targeted screening.In 2019, the team reported early findings from the international IMPACT study, which showed that men with BRCA2 mutations have such a high risk of aggressive prostate cancers that they should be offered annual PSA testing. The study found that PSA testing picked up prostate cancers more often and at a younger age in these men. Now, the latest results from the study – presented at the European Society for Medical Oncology (ESMO) Congress 2025 – show that men with BRCA1 mutations should also be offered an annual PSA test.The IMPACT study assessed the potential benefits of PSA testing in men with BRCA1 and BRCA2 mutations at 65 centres in 20 different countries around the world.Men with the BRCA1 gene fault were more than three times as likely, compared with non-carriers, to have aggressive prostate cancers that are likely to grow and spread quickly.There was no difference in the age of diagnosis or the risk of developing prostate cancer for BRCA1 carriers compared with non-carriers.The latest findings confirm the need for PSA testing in BRCA2 carriers – the risk of prostate cancer is more than doubled, from 1.4 per cent to 3,1 per cent, and the average age of diagnosis is 60 for carriers, compared with 65 for non-carriers.While more accurate tests – such as a saliva test to detect genetic risk of cancer – are being trialled, targeted screening using a PSA test for those at the highest risk, including BRCA1 gene fault carriers, could significantly improve early detection of the disease.Professor Ros Eeles, Professor of Oncogenetics at The Institute of Cancer Research, London, who leads the IMPACT study, said:“Our research shows that men with BRCA1 and BRCA2 mutations face a significantly higher risk of aggressive prostate cancer. Until more accurate diagnostic tests become available, targeted PSA screening in this high-risk group could detect these cancers earlier, when treatment is more effective.“We are urging regulatory bodies to act on the evidence and update current guidance so that all men from 40 years with a BRCA1 or BRCA2 mutation are offered annual PSA testing. We are expecting an update to this guidance soon, and we hope to see the inclusion of BRCA carriers in any targeted screening programme, to give these men more control over their health and improve timely diagnosis.”Tony McHale, 74, discovered he had an alteration in the BRCA2 gene when he was 61. Shortly after, he was invited to join the IMPACT study. The annual PSA test and follow-up checks revealed, 18 months later, that he had prostate cancer. Tony said, “I couldn’t believe it. I felt completely fine, and I had no symptoms. I was immediately given a three-month course of intensive radiotherapy treatment. When it ended, I was told I was clear of cancer. It was a fantastic moment. I cried with relief. It felt like I’d been given a new lease of life. Being involved in the IMPACT study saved my life. If I hadn’t taken part, I’d never have known I had prostate cancer. As far as I was aware, I didn’t have any symptoms – and the sooner the disease is detected and treated, the better the chances are of survival.” - Source: oncologynews.com.auDid you know?Less likelyMen who were offered PSA screening were 13% less likely to die from prostate cancer than those who weren’t screened.

Men with BRCA1 and BRCA2 gene mutations should get annual prostate cancer screening

Kommentaar

Republikein 2026-01-29

Meld asseblief aan om kommentaar te lewer

Men with BRCA1 and BRCA2 gene mutations should get annual prostate cancer screening

Kommentaar

Republikein 2026-01-29

Meld asseblief aan om kommentaar te lewer

Intekening vereis om toegang tot inhoud te kry. ×

MELD AAN

Advertensie

Intekening vereis om toegang tot inhoud te kry.